Form 8-K - Current report:
SEC Accession No. 0000950170-25-096645
Filing Date
2025-07-17
Accepted
2025-07-17 17:00:32
Documents
10
Period of Report
2025-07-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20250717.htm   iXBRL 8-K 66745
  Complete submission text file 0000950170-25-096645.txt   209154

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20250717.xsd EX-101.SCH 47021
12 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20250717_htm.xml XML 6609
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 251131323
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)